GSK halts breast cancer trial following positive results

GlaxoSmithKline halted trials of its breast cancer drug Tykerb in women whose cancer had spread to other body parts because of good results, the UK drug maker said. Tykerb showed a 50% slowdown of the progression of advanced breast cancer in women who have failed on ordinary chemotherapy and Herceptin. “A pre-planned interim analysis of 321 patients in the study yielded statistically significant results, exceeding the primary endpoint,” GlaxoSmithKline said in a statement. GlaxoSmithKline said it plans to file for regulatory approval for Tykerb in the US and Europe later this year.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.